3 New Strong Buy Ratings from Top-Rated Analysts: 07/22/2026
Most investors have never heard of these names … Yet they have very high potential. Let’s get to ‘em:
- InfuSystem Holdings (INFU): Affordable stock with BIG upside targets
- Neurocrine Biosciences (NBIX): 18 analysts bullish, zero say sell
- Tapestry (TPR): Coach's parent could climb over 60%
P.S. Speaking of stocks to check out today … Check out these.
A note from our sponsors...
The ONLY AI opportunity you should be looking at
This is the ONLY AI wealth-building opportunity you should be watching right now.
No. It's not about Nvidia, Tesla, or Meta...
It's about one overlooked company profiting off AI "digital goldmines" that are poised to experience 100x growth very soon.
This new opportunity will change the market and make investors a lot of money.
That's why it has received a $500 billion commitment from President Trump himself...
Learn more about this little-known company here >>>
1. Infusystem Holdings (NYSEMKT: INFU)
This health services company is benefiting from improved treatment volumes in its patient services business and growing sales of medical equipment, positioning it as the highest-rated stock in the Medical industry with substantial upside potential.
Zen Rating: A (Strong Buy) — see full analysis
Recent Price: $8.94 — get current quote
Max 1-year forecast: $15.00
Why we're watching:
- INFU has limited, but overall bullish, coverage among the analysts we track, with 1 Strong Buy recommendation. See all recommendations here
- For example, Roth Capital researcher Kyle Bauser (a top 19% rated analyst) reiterated his Strong Buy rating with a price target suggesting nearly 70% upside potential from current levels.
- Industry ranking context: INFU is currently the #2 highest-rated stock in the Medical industry, which has an Industry Rating of B.
- Zen Ratings highlights: INFU earns an overall A rating, which is equal to a Strong Buy recommendation. Stocks with this rating have historically delivered nearly 30% annual returns, significantly outperforming the broader market.
- Component Grades: INFU excels with outstanding As for Financials and Sentiment, reflecting the company's strong execution and positive analyst outlook, while also maintaining solid Bs for Safety and Value, a combination that suggests favorable risk-adjusted return potential. See all 7 Component Grades here
2. Neurocrine Biosciences (NASDAQ: NBIX)
With a robust pipeline and strong financial performance, this pharma company is attracting broad analyst support as it continues to expand its market presence in specialized therapeutic areas.
Zen Rating: A (Strong Buy) — see full analysis
Recent Price: $175.48 — get current quote
Max 1-year forecast: $246.00
Why we're watching:
- NBIX has strong, bullish coverage among the analysts we track, with 9 Strong Buy, 7 Buy, and 2 Hold recommendations. See all recommendations here
- For example, Wells Fargo researcher Mohit Bansal (a top 13% rated analyst) recently maintained his Strong Buy rating with a price target suggesting the stock could see close to 20% upside in the coming year.
- Separately, Truist Securities researcher Danielle Brill (a top 10% rated analyst) maintained her Strong Buy with a similar price target.
- Industry ranking context: NBIX is currently the #2 highest-rated stock in the Pharmaceutical industry, which has an Industry Rating of C.
- Zen Ratings highlights: NBIX earns an overall A rating, which is a Strong Buy recommendation. This designation reflects the company's passage of a rigorous 115-factor fundamental analysis, placing it in the elite upper echelon of tracked equities.
- Component Grades: NBIX excels with exceptional A for Artificial Intelligence highlighting the company's strategic positioning in AI-driven drug development and attractive valuation metrics, while also earning strong Bs for Financials, Value, and Growth. See all 7 Component Grades here
3. Tapestry (NYSE: TPR)
You might not recognize the name Tapestry, but you probably know some of its brands: Coach, Kate Spade, and Stuart Weitzman. The company is demonstrating strong execution across its premium brand portfolio, with analysts citing robust earnings growth potential and market share expansion opportunities in the luxury segment.
Zen Rating: A (Strong Buy) — see full analysis
Recent Price: $141.41 — get current quote
Max 1-year forecast: $230.00
Why we're watching:
- TPR has broad, bullish coverage among the analysts we track, with 8 Strong Buy and 3 Buy recommendations. See all recommendations here
- For example, Barclays researcher Adrienne Yih (a top 3% rated analyst) recently maintained her Strong Buy rating with a price target suggesting the stock could see nearly 30% upside in the coming year.
- Even more impressive in terms of upside potential, UBS researcher Jay Sole (a top 7% rated analyst) maintained his Strong Buy with a target that suggests the stock could see roughly 60% upside in the coming year.
- Industry ranking context: TPR is currently the #2 highest-rated stock in the Luxury industry, which has an Industry Rating of A.
- Zen Ratings highlights: TPR earns an overall A rating, which amounts to a Strong Buy recommendation. This places the stock among the top 5% of all equities tracked following a comprehensive fundamental review across 115 distinct factors.
- Component Grades: TPR excels with an outstanding A for Financials, reflecting the company's exceptional profitability and operational efficiency in the luxury goods sector, while maintaining solid Bs for Artificial Intelligence, Growth, and Sentiment. See all 7 Component Grades here
What to Do Next?
Want to get in touch? Email us at news@wallstreetzen.com.
Keep Reading
See All News
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.